Bacterial Conjunctivitis drugs in development, 2023
The Bacterial Conjunctivitis drugs in development market research report provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bacterial Conjunctivitis. Buy the report here.The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued products.GlobalData tracks six drugs in development for Bacterial Conjunctivitis by six companies/universities/institutes. The top development phase for Bacterial Conjunctivitis is preclinical with three drugs in that stage. The Bacterial Conjunctivitis pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bacterial Conjunctivitis pipeline products market are: NTC, TaeJoon Pharmaceuticals and Cellics Therapeutics.The key targets in the Bacterial Conjunctivitis pipeline products market include DNA Topoisomerase IV (EC 5.99.1.3), DNA Gyrase (EC 5.99.1.3), and DNA Primase (EC 2.7.7.6).The key mechanisms of action in the Bacterial Conjunctivitis pipeline product include DNA Topoisomerase IV (EC 5.99.1.3) Inhibitor with two drugs in Phase II. The Bacterial Conjunctivitis pipeline products include six routes of administration with the top ROA being Ophthalmic and two key molecule types in the Bacterial Conjunctivitis pipeline products market including Small Molecule, and Biologic.Bacterial Conjunctivitis overviewBacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, less commonly, Chlamydia trachomatis. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light, and burning eyes. Treatment includes antibiotics.For a complete picture of Bacterial Conjunctivitis's pipeline drug market, buy the report here.
GlobalData tracks 6 drugs in development for Bacterial Conjunctivitis by six companies/universities/institutes. The top development phase for Bacterial Conjunctivitis is preclinical, with three drugs in that stage.
What's Your Reaction?
